Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
Biogen (BIIB) Stock Price & Analysis
4,422 Followers
BIIB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$189.44 - $280.42
Previous Close$226.4
Volume851.79K
Average Volume (3M)1.09M
Market Cap
$32.96B
Enterprise Value$40.30B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$7.34B
Price to Earnings (P/E)28.3
Beta0.50
Next Earnings
Aug 01, 2024Last Dividend Ex-Date
Feb 02, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)8.01
Shares Outstanding145,596,895
10 Day Avg. Volume1,103,036
30 Day Avg. Volume1,092,429
Standard Deviation0.10
R-Squared0.00011
Alpha0.00495
Financial Highlights & Ratios
Price to Book (P/B)150.16
Price to Sales (P/S)3.32
Price to Cash Flow (P/CF)652.30
P/FCF Ratio956.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.73
Enterprise Value/Gross Profit5.52
Enterprise Value/Ebitda18.80
Forecast
1Y Price Target
$284.40Price Target Upside25.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering24
Biogen News
Bulls Say, Bears Say
Bulls Say
Market ExpansionDonanemab approval is expected to grow the market, providing additional support for the amyloid hypothesis.
Sales GrowthLeqembi's sales trajectory aligns with guidance, indicating realistic and achievable growth.
Strategic AcquisitionsThe announced acquisition of HI-Bio for $1.15B significantly enhances Biogen's presence in the immune space without substantially increasing debt.
Bears Say
FDA DecisionsFDA delayed their decision for a third time and called for an advisory committee, indicating hesitation on the FDA's part regarding the safety profile of donanemab.
Patient UptakeBiogen expects patient uptake for Skyclarys to be 'lumpy' due to adverse events and lack of compliance, which could hinder growth.
Sales PerformanceBiogen's 4Q23 earnings were disappointing, with a miss on the top and bottom lines and weaker-than-expected Leqembi, Skyclarys and Spinraza sales, the most important franchises for the company.
---
Ownership Overview
1.99% Insiders
37.18% Mutual Funds
28.09% Other Institutional Investors
32.74% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BIIB FAQ
What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $189.44 and its highest was $280.42 in the past 12 months.
What is Biogen’s market cap?
Currently, no data Available
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is Aug 01, 2024 which is in 10 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Apr 24, 2024. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $3.47 by $0.2.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen pays a Notavailable dividend of $22.23 which represents an annual dividend yield of N/A. See more information on Biogen dividends here
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is $4.
How many shares outstanding does Biogen have?
Biogen has 145,596,900 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $3.67 in its last earnings report, beating expectations of $3.47. Following the earnings report the stock price went up 4.561%.
Which hedge fund is a major shareholder of Biogen?
Among the largest hedge funds holding Biogen’s share is PRIMECAP Management Co. It holds Biogen’s shares valued at 3B.
---
Biogen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$284.40 (25.62% Upside)
$284.40 (25.62% Upside)
Blogger Sentiment
Bullish
BIIB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 128.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.23%
12-Months-Change
Fundamentals
Return on Equity
8.04%
Trailing 12-Months
Asset Growth
8.01%
Trailing 12-Months
Company Description
Biogen
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
---
BIIB Company Deck
---
BIIB Earnings Call
Q1 2024
0:00 / 0:00
---
BIIB Revenue Breakdown
73.68% Product revenue
17.18% Revenue from anti-CD20 therapeutic programs
9.14% Other
---
BIIB Stock 12 Month Forecast
Average Price Target
$284.40
▲(25.62% Upside)
Technical Analysis
Best Analysts Covering BIIB
1 Year
---